Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Src RNAi refers to RNA interference-based molecules, such as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), that specifically target and silence the expression of the Src gene (Proto-oncogene tyrosine-protein kinase Src). Src is a non-receptor tyrosine kinase that plays a critical role in regulating cellular processes including proliferation, differentiation, and motility. In oncology research, Src RNAi is used to study the signaling pathways involved in tumor invasion and metastasis. Research in bladder cancer has indicated that Src may act as a metastasis suppressor in certain urothelial contexts, where its knockdown via RNAi leads to increased RhoA and RhoC activity and enhanced cell migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Src RNAi.